Study of immune drug and aspirin for Hard-to-Treat breast cancer canceled
NCT ID NCT04188119
First seen Dec 11, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study was designed to see if combining an immunotherapy drug (avelumab) with aspirin could help the immune system fight triple-negative breast cancer, a type that doesn't respond to hormone therapy. It planned to enroll women aged 18 and older with confirmed triple-negative breast cancer. Participants would receive either avelumab alone or with aspirin, and researchers would compare immune changes in tissue and blood samples. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.